异基因造血干细胞移植治疗获得性重型再生障碍性贫血的研究进展

国际输血及血液学杂志 Pub Date : 2019-09-20 DOI:10.3760/CMA.J.ISSN.1673-419X.2019.05.015

Zhengna Yin, G. Zhang, H. Meng, Wei Yang, Yicheng Wang

{"title":"异基因造血干细胞移植治疗获得性重型再生障碍性贫血的研究进展","authors":"Zhengna Yin, G. Zhang, H. Meng, Wei Yang, Yicheng Wang","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.05.015","DOIUrl":null,"url":null,"abstract":"Acquired severe aplastic anemia (SAA) is a life-threatening bone marrow failure syndrome. Immunosuppressive therapy (IST) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) are the main treatments for acquired SAA. Matched sibling donor (MSD)-hematopoietic stem cell transplantation (HSCT) is the best treatment for acquired SAA patients who are younger than 40 years old. Outcomes of unrelated donor (URD)-HSCT, haploidentical hematopoietic stem cell transplantation (haplo-HSCT) and umbilical cord blood transplantation (UCBT) have improved in the recent decade, and provide more options with respect to the clinical treatment of acquired SAA. In order to improve clinicians′ understanding of allo-HSCT for acquired SAA, this article reviews the research progress of acquired SAA treated by allo-HSCT in recent years. \n \n \nKey words: \nAnemia, aplastic; Hematopoietic stem cell transplantation; Donor selection; Transplantation conditioning; Graft vs host disease; Transplantation, haploidentical; Cord blood stem cell transplantation","PeriodicalId":13774,"journal":{"name":"国际输血及血液学杂志","volume":"42 1","pages":"450-456"},"PeriodicalIF":0.0000,"publicationDate":"2019-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advances in allogeneic hematopoietic stem cell transplantation in treatment of acquired severe aplastic anemia\",\"authors\":\"Zhengna Yin, G. Zhang, H. Meng, Wei Yang, Yicheng Wang\",\"doi\":\"10.3760/CMA.J.ISSN.1673-419X.2019.05.015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Acquired severe aplastic anemia (SAA) is a life-threatening bone marrow failure syndrome. Immunosuppressive therapy (IST) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) are the main treatments for acquired SAA. Matched sibling donor (MSD)-hematopoietic stem cell transplantation (HSCT) is the best treatment for acquired SAA patients who are younger than 40 years old. Outcomes of unrelated donor (URD)-HSCT, haploidentical hematopoietic stem cell transplantation (haplo-HSCT) and umbilical cord blood transplantation (UCBT) have improved in the recent decade, and provide more options with respect to the clinical treatment of acquired SAA. In order to improve clinicians′ understanding of allo-HSCT for acquired SAA, this article reviews the research progress of acquired SAA treated by allo-HSCT in recent years. \\n \\n \\nKey words: \\nAnemia, aplastic; Hematopoietic stem cell transplantation; Donor selection; Transplantation conditioning; Graft vs host disease; Transplantation, haploidentical; Cord blood stem cell transplantation\",\"PeriodicalId\":13774,\"journal\":{\"name\":\"国际输血及血液学杂志\",\"volume\":\"42 1\",\"pages\":\"450-456\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"国际输血及血液学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.05.015\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际输血及血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.05.015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

获得性严重再生障碍性贫血(SAA)是一种危及生命的骨髓衰竭综合征。免疫抑制疗法(IST)和同种异体造血干细胞移植(alloc - hsct)是获得性SAA的主要治疗方法。匹配兄弟姐妹供体(MSD)-造血干细胞移植(HSCT)是40岁以下获得性SAA患者的最佳治疗方法。近十年来，非亲属供体(URD)-HSCT、单倍体造血干细胞移植(haploo -HSCT)和脐带血移植(UCBT)的结果有所改善，为获得性SAA的临床治疗提供了更多选择。为了提高临床医生对同种异体造血干细胞移植治疗获得性SAA的认识，本文综述了近年来同种异体造血干细胞移植治疗获得性SAA的研究进展。关键词:贫血;再生;造血干细胞移植;供选择;移植条件;移植物抗宿主病;移植,同一性;脐带血干细胞移植

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Advances in allogeneic hematopoietic stem cell transplantation in treatment of acquired severe aplastic anemia

Acquired severe aplastic anemia (SAA) is a life-threatening bone marrow failure syndrome. Immunosuppressive therapy (IST) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) are the main treatments for acquired SAA. Matched sibling donor (MSD)-hematopoietic stem cell transplantation (HSCT) is the best treatment for acquired SAA patients who are younger than 40 years old. Outcomes of unrelated donor (URD)-HSCT, haploidentical hematopoietic stem cell transplantation (haplo-HSCT) and umbilical cord blood transplantation (UCBT) have improved in the recent decade, and provide more options with respect to the clinical treatment of acquired SAA. In order to improve clinicians′ understanding of allo-HSCT for acquired SAA, this article reviews the research progress of acquired SAA treated by allo-HSCT in recent years. Key words: Anemia, aplastic; Hematopoietic stem cell transplantation; Donor selection; Transplantation conditioning; Graft vs host disease; Transplantation, haploidentical; Cord blood stem cell transplantation

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

国际输血及血液学杂志

自引率

0.00%

发文量

10610

期刊介绍： The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.